Does Fidaxomicin Therapy Reduce Spread of Clostridium Difficile?

CompletedOBSERVATIONAL
Enrollment

203

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2017

Conditions
Clostridium Difficile Infection
Interventions
OTHER

Environmental sampling

Sampling of five sites in the patient's immediate environment for C. difficile spores

OTHER

Skin swab sampling

Collection of swabs from three sites on the skin for C. difficile spores

OTHER

Fecal sampling

Collection of fecal samples for C. difficile spores

Trial Locations (3)

SW19 0QT

St George's University Hospitals NHS Foundation Trust, Tooting

BD9 6RJ

Bradford Teaching Hospitals NHS Foundation Trust, Bradford

LS1 3EX

Leeds Teaching Hospitals NHS Trust, Leeds

All Listed Sponsors
collaborator

Astellas Pharma Europe Ltd.

INDUSTRY

collaborator

The Leeds Teaching Hospitals NHS Trust

OTHER

collaborator

St George's Healthcare NHS Trust

OTHER

lead

Professor Mark Wilcox

OTHER

NCT02461901 - Does Fidaxomicin Therapy Reduce Spread of Clostridium Difficile? | Biotech Hunter | Biotech Hunter